Tests elecoglipron against placebo in adults with chronic kidney disease
Tests elecoglipron versus placebo in adults with chronic kidney disease, alongside standard care.
Key facts
- Who runs it
- AstraZeneca
- Where
- Helsinki, Jyväskylä, Oulu, Tampere, and Turku, FinlandSee the 6 sitesAlso in 36 other countries, 608 sites
- Trial code
- Registry title
- A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 7,000 people, planned
- Started
- 21 Aug 2026
- Expected to end
- 4 Oct 2030
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Elecoglipron
- Placebo
- Record updated
- 9 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with chronic kidney disease, with or without type 2 diabetes, who already take a daily ACE inhibitor or ARB. It compares elecoglipron with placebo.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Confirmed chronic kidney disease with UACR ≥30 mg/g and eGFR ≥20 mL/min/1.73 m² within specified ranges
- Earlier treatment
- Must be on a stable, maximum tolerated, labeled daily dose of an ACE inhibitor or ARB for ≥4 weeks, at least 28 days before screening
- Biomarker or test result
- UACR ≥30 mg/g and eGFR ≥20 mL/min/1.73 m²
Main reasons for not taking part
- BMI <23 kg/m² at screening
- History of type 1 diabetes
- HbA1c ≥10% (86 mmol/mol) at screening
- History of pancreatitis, or personal or family history (first degree) of medullary thyroid cancer or MEN2
- Heart attack-type event, major cardiac procedure, stroke or TIA within 3 months before screening
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Adults with confirmed CKD; UACR ≥30 mg/g and eGFR ≥20 mL/min/1.73 m² within specified ranges
- On stable, patient maximum tolerated, labeled daily dose of ACEI or ARB for ≥4 weeks at least 28 days before screening
Who cannot take part
- Currently receiving, or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema
- Have had more than one episode of severe hypoglycemia within 180 days prior to screening, or hypoglycemia unawareness
- Acute coronary syndrome, major cardiac procedure, stroke, or TIA within 3 months prior to screening
- History of type 1 diabetes mellitus
- Clinically significant condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying
- History of acute or chronic pancreatitis
- History/family history (first degree) of medullary thyroid cancer or MEN2
- HbA1c ≥10% (86 mmol/mol) at screening
- BMI <23 kg/m² at screening
Where in Finland
Also in 36 other countries, 608 sites
- HUS-YhtymaeHelsinki, FinlandTaking people
- Studycor OyJyväskylä, FinlandTaking people
- Oulu University HospitalOulu, FinlandTaking people
- Suomen Terveystalo OyTampere, FinlandTaking people
- Tampere University HospitalTampere, FinlandTaking people
- Suomen Terveystalo OyTurku, FinlandTaking people
About the trial
What the trial wants to find out
This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled multicenter study to investigate outcomes with elecoglipron compared with placebo in participants with CKD with and without T2DM who are on background SGLT2i (dapagliflozin) as GDMT and other SoC treatments for CKD.
The 2 groups in the trial
- ElecoglipronTreatment being tested
Elecoglipron tablet once daily
- PlaceboExisting treatment, for comparison
Placebo matching Elecoglipron tablet once daily
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
- Official title
- A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Renal Outcomes and Mortality in Participants With Chronic Kidney Disease (Elevate-CKD)
- Plain-language title
- Tests elecoglipron against placebo in adults with chronic kidney diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 9 September 2026